Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives

Autor: Steven M. Kwasny, Timothy J. Opperman, Xiaoyuan Ding, Hanno Sjuts, Terry L. Bowlin, Alina R. Ornik, Attilio Vittorio Vargiu, Son T. Nguyen, Paolo Ruggerone, Hiroshi Nikaido, Hong-Suk Kim, Klaas M. Pos
Rok vydání: 2016
Předmět:
0301 basic medicine
Models
Molecular

Cell division
Pyridines
Drug Resistance
medicine.disease_cause
Crystallography
X-Ray

Models
Drug Resistance
Multiple
Bacterial

Drug Discovery
efflux pump inhibitors
Crystallography
Multidisciplinary
Escherichia coli Proteins
Bacterial
Biological Sciences
Anti-Bacterial Agents
Infectious Diseases
molecular dynamics simulation
Biochemistry
5.1 Pharmaceuticals
Efflux
Multidrug Resistance-Associated Proteins
Infection
Multiple
Hydrophobic and Hydrophilic Interactions
Protein Structure
Stereochemistry
030106 microbiology
Drug design
Biology
Molecular Dynamics Simulation
Vaccine Related
03 medical and health sciences
multidrug resistance
Biodefense
medicine
Escherichia coli
Humans
Antibacterial drug
RND efflux transporters
X-ray crystallography
Pyrans
Binding Sites
Prevention
Molecular
Periplasmic space
biology.organism_classification
Protein Structure
Tertiary

Multiple drug resistance
Emerging Infectious Diseases
030104 developmental biology
ddc:000
X-Ray
Antimicrobial Resistance
Tertiary
Bacteria
Zdroj: Sjuts, H; Vargiu, AV; Kwasny, SM; Nguyen, ST; Kim, HS; Ding, X; et al.(2016). Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives. Proceedings of the National Academy of Sciences of the United States of America, 113(13), 3509-3514. doi: 10.1073/pnas.1602472113. UC Berkeley: Retrieved from: http://www.escholarship.org/uc/item/36v4w9g5
Proceedings of the National Academy of Sciences of the United States of America, vol 113, iss 13
Proceedings of the National Academy of Sciences of the United States of America 113(13), 3509-3514 (2016). doi:10.1073/pnas.1602472113
ISSN: 1091-6490
Popis: Proceedings of the National Academy of Sciences of the United States of America 113(13), 3509 - 3514(2016). doi:10.1073/pnas.1602472113
The Escherichia coli AcrAB-TolC efflux pump is the archetype of the resistance nodulation cell division (RND) exporters from Gram-negative bacteria. Overexpression of RND-type efflux pumps is a major factor in multidrug resistance (MDR), which makes these pumps important antibacterial drug discovery targets. We have recently developed novel pyranopyridine-based inhibitors of AcrB, which are orders of magnitude more powerful than the previously known inhibitors. However, further development of such inhibitors has been hindered by the lack of structural information for rational drug design. Although only the soluble, periplasmic part of AcrB binds and exports the ligands, the presence of the membrane-embedded domain in AcrB and its polyspecific binding behavior have made cocrystallization with drugs challenging. To overcome this obstacle, we have engineered and produced a soluble version of AcrB [AcrB periplasmic domain (AcrBper)], which is highly congruent in structure with the periplasmic part of the full-length protein, and is capable of binding substrates and potent inhibitors. Here, we describe the molecular basis for pyranopyridine-based inhibition of AcrB using a combination of cellular, X-ray crystallographic, and molecular dynamics (MD) simulations studies. The pyranopyridines bind within a phenylalanine-rich cage that branches from the deep binding pocket of AcrB, where they form extensive hydrophobic interactions. Moreover, the increasing potency of improved inhibitors correlates with the formation of a delicate protein- and water-mediated hydrogen bond network. These detailed insights provide a molecular platform for the development of novel combinational therapies using efflux pump inhibitors for combating multidrug resistant Gram-negative pathogens.
Published by National Acad. of Sciences, Washington, DC
Databáze: OpenAIRE